Abatacept Prevents Severe Acute Graft‐Versus‐Host Disease Without Increasing Graft Failure Risk in Pediatric Bone Marrow Failure Syndromes
ABA was well tolerated in patients with BMFS and prevented severe acute GVHD without increasing the incidence of graft failure. Rates of chronic GVHD and GFS at 1 year were similar, but analysis was limited due to sample size and variability in ABA dosing.
Authors
- Kasiani C. Myers (ORCID: https://orcid.org/0000-0002-5528-4405)
- Eric Anderson
- Stella M. Davies (ORCID: https://orcid.org/0000-0002-3137-6647)
- Deborah Schiff (ORCID: https://orcid.org/0000-0003-3154-8987)
- Nicholas J. Gloude (ORCID: https://orcid.org/0000-0002-8105-7011)
- Adam Lane (ORCID: https://orcid.org/0000-0002-5522-8112)
- Zahra Hudda (ORCID: https://orcid.org/0009-0002-1117-7314)
- Parinda A. Mehta
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-09-28
- DOI
- https://doi.org/10.1002/pbc.32085
- Citations
- 1
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.77